Discovering Therapeutic Advantage
Through Innovations in Drug Delivery

Product Strategy

Discovering Therapeutic Advantage
Through Innovations in Drug Delivery

Product Pipeline

Kenox business model is to develop innovative and improved therapies for unmet medical needs and/or for better patient outcomes. We repurpose approved drugs to intranasal and inhalation routes using innovative formulations and/or devices/drug delivery systems, and thereby enhancing therapeutic efficacy and/or decreasing adverse effects. We have a portfolio of 4 NDA 505(b)(2) products in different stages of pre-clinical development. Our target indications include Non small cell lung cancer (adjuvant therapy), Nicotine replacement therapy, and Restless leg syndrome.

 

Please reach out to bd@kenoxpharma.us to learn more about Kenox pipeline and partnering opportunities.